أعرض في EDS

Comparative Incidence and Health Care Costs of Medically Attended Adverse Effects among U.S. Medicaid HIV Patients on Atazanavir- or Darunavir-Based Antiretroviral Therapy

التفاصيل البيبلوغرافية
العنوان: Comparative Incidence and Health Care Costs of Medically Attended Adverse Effects among U.S. Medicaid HIV Patients on Atazanavir- or Darunavir-Based Antiretroviral Therapy
المؤلفون: Jonathan Uy, Timothy Juday, Stephen S. Johnston, Derek Espindle, Bong-Chul Chu, Stephen Esker, Tony Hebden
المصدر: Value in Health. 16:418-425
بيانات النشر: Elsevier BV, 2013.
سنة النشر: 2013
مصطلحات موضوعية: Adult, Male, Pediatrics, medicine.medical_specialty, Adolescent, Anti-HIV Agents, Gastrointestinal Diseases, Pyridines, antiretroviral therapy, Atazanavir Sulfate, Lipid Metabolism Disorders, Jaundice, HIV Infections, Insurance Claim Review, Young Adult, Health care, Humans, Medicine, Adverse effect, atazanavir, Darunavir, Glucose Metabolism Disorders, Retrospective Studies, Sulfonamides, Medicaid, business.industry, Health Policy, Incidence (epidemiology), Hazard ratio, Public Health, Environmental and Occupational Health, Health Care Costs, Exanthema, Middle Aged, United States, Atazanavir, Tolerability, adverse effects, Female, business, Oligopeptides, medicine.drug
الوصف: ObjectivesThis is the first study to compare the incidence and health care costs of medically attended adverse effects in atazanavir- and darunavir-based antiretroviral therapy (ART) among U.S. Medicaid patients receiving routine HIV care.MethodsThis was a retrospective study using Medicaid administrative health care claims from 15 states. Subjects were HIV patients aged 18 to 64 years initiating atazanavir- or darunavir-based ART from January 1, 2003, to July 1, 2010, with continuous enrollment for 6 months before (baseline) and 6 months after (evaluation period) ART initiation and 1 or more evaluation period medical claim. Outcomes were incidence and health care costs of the following medically attended (International Classification of Diseases, Ninth Revision, Clinical Modification–coded or treated) adverse effects during the evaluation period: gastrointestinal, lipid abnormalities, diabetes/hyperglycemia, rash, and jaundice. All-cause health care costs were also determined. Patients treated with atazanavir and darunavir were propensity score matched (ratio = 3:1) by using demographic and clinical covariates. Multivariable models adjusted for covariates lacking postmatch statistical balance.ResultsPropensity-matched study sample included 1848 atazanavir- and 616 darunavir-treated patients (mean age 41 years, 50% women, 69% black). Multivariable-adjusted hazard ratios (HRs) (for darunavir, reference = atazanavir) and per-patient-per-month health care cost differences (darunavir minus atazanavir) were as follows: gastrointestinal, HR = 1.25 (P = 0.04), $43 (P = 0.13); lipid abnormalities, HR = 1.38 (P = 0.07), $3 (P = 0.88); diabetes/hyperglycemia, HR = 0.84 (P = 0.55), $13 (P = 0.69); and rash, HR = 1.11 (P = 0.23), $0 (P = 0.76); all-cause health care costs were $1086 (P
تدمد: 1098-3015
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6921b55f7fb5e562126604aaff4ce212
https://doi.org/10.1016/j.jval.2012.10.021
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....6921b55f7fb5e562126604aaff4ce212
قاعدة البيانات: OpenAIRE
الوصف
تدمد:10983015